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The natural history of cystic fibrosis (CF) is unpredictable and the optimal timing for lung trans-
plantation in end-stage disease uncertain. Predicting survival based on FEV1 alone remains
controversial and therefore the aim of this study was to assess the value of walk test perfor-
mance in pre-transplant assessment.
Retrospective review of adult patients with end-stage CF who underwent transplant assess-
ment between 1988 and 2004 including a documented walk test on room air, but who died
before transplant. The six-minute walk test (6MWT) was used between 1988 and 1993 and
the shuttle walk test (SWT) thereafter, the two cohorts were therefore individually assessed.
A total of 121 patients were identified. The median (IQR) survival in patients performing SWT
(nZ 77) and 6MWT (nZ 44) was 363 days (226, 566) and 433 days (232, 844), respectively, with
survival in both cohorts significantly associated with pre-test (resting) heart rate (HR)
(p< 0.03), but not distance walked, pre-test SpO2, FEV1 or BMI. It was predicted that 85% of
patients performing SWT with a resting HR of 120 bpm, 70% of those with a HR of 109 bpm
(cohort median) but only 25% with a HR of 72 bpm would die within 500 days. Distance walked
in the SWT was significantly related to pre-test HR (p< 0.01), SpO2 (p< 0.01) and Borg score
(pZ 0.016) when performing linear regression. Only pre-test HR remained significant when
performing multiple regression.
Resting heart rate was the only consistent parameter in this study at predicting a high risk of
dying on the transplant waiting list.
ª 2009 Elsevier Ltd. All rights reserved.CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in
art rate; IQR, interquartile range; PaO2, arterial partial pressure of oxygen; PaCO2, arterial partial
oxygen saturation; SWT, shuttle walk test; 6MWT, six-minute walk test.
ress: Department of Cystic Fibrosis, University Hospital Llandough, Penlan Road, Penarth CF64 2XX,
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Predicted survival in patients with cystic fibrosis (CF) has
doubled over the last 30 years from a median age of only 16
years in the early 1970’s to over 32 years.1 Respiratory
failure remains the primary cause of mortality, with lung
transplantation the only hope of improved survival.2 The
natural history of CF, however, remains unpredictable and
with transplant waiting times increasing and donor organ
availability in the UK decreasing, it is difficult to predict the
optimal timing for assessment and transplantation in end-
stage disease. A late referral puts the patient at risk of
dying on a waiting list, but transplanting a patient too early
puts the patient at significant risk from potential post-
operative complications and may reduce overall survival.
Selection criteria for lung transplantation were intro-
duced by an international consensus committee in 1998
(updated in 2006) based on lung function, arterial blood gas
measurement and clinical characteristics.3,4 However,
predicting mortality and thereby identifying patients at
high risk of dying on the waiting list utilising these param-
eters remains contentious.4,5
Walk tests provide a simple and reproducible measure of
functional capacity in cardiorespiratory disease which may
provide additional insight into those at greatest risk of
dying whilst on a transplant waiting list.6e11 In this retro-
spective study the utility of the incremental shuttle walk
test, the six-minute walk test and resting clinical parame-
ters performed as part of a pre-transplant assessment in
patients with end-stage CF were evaluated.
Methods
This study has received a favourable opinion from the Royal
Brompton and Harefield NHS Trust and National Heart and
Lung Institute Ethics Committee.
Subjects
The medical records of all adult patients with end-stage CF
who died whilst on the Royal Brompton and Harefield
Hospital lung transplant waiting list between July 1988 and
June 2004 were reviewed. Selection criteria for lung
transplant assessment throughout the study period were
consistent with the current guidelines.3,4
Functional data
Data collated included spirometry (Vitalograph; Bucking-
ham, UK), arterial blood gas measurement on room air
(Rapidlab 348; Bayer, UK) and body mass index as docu-
mented in the transplant assessment document.
Walk tests
Two walk tests have been utilised at the Royal Brompton
Hospital since 1988, the six-minute walk test (6MWT) from
1988 to 1993 and the shuttle walk test (SWT) from 1994 to
the present day. Walk tests have been performed as part of
each patient’s annual review as well as during transplant
assessment over the last 15 years. Walk tests were notalways repeated as part of the transplant assessment if
they had been performed within three months as part of an
annual review. Only data from patients performing walk
tests on room air were included in the analysis. All patients
were fully rested for at least 20 min before each test and
were requested to withhold bronchodilators prior to the
test. Heart rate was continuously monitored whilst sitting
quietly during the rest period to achieve stability and
during the walk test to record the highest heart rate.
The shuttle walk test
This constitutes a standardised incremental field exercise
test described by Singh et al., which provokes a symptom
limited maximal performance.12 Patients are required to
walk around a level 10 m course, defined by two cones
along a hospital corridor. It is externally paced by a timed
signal played on a cassette recorder and is progressive,
increasing in speed every minute with the complete test
lasting 12 min to a maximal possible distance of 1020 m.
The end point of the test is determined either by the
patient becoming too breathless to maintain the required
speed, or by the operator when the patient fails to
complete the shuttle in the time allowed (the patient is
more than 0.5 m away from the cone when the signal
sounds), or if oxygen saturation falls below 75%. Measure-
ments recorded include distance walked (number of
shuttles 10 m), pre- and post-test oxygen saturations
(SpO2) using a hand-held oximeter (Nellcor NPB-40 from
1998, previously Nellcor N-200, Tyco Healthcare UK Ltd.),
pre- and post-test heart rate and level of perceived
breathlessness as measured by the Borg scale and subjec-
tive and objective recovery times.13,14 Patients performing
a SWT for the first time had a practice walk first with at
least a further 45 min rest before the actual test.
The six-minute walk test
This test is based on the 12-min walk test described by
McGavin et al.15 Patients are instructed to walk around
a level 30 m course defined by two cones along a hospital
corridor for 6 min. In contrast to the SWT, patients walk at
their own pace and can slow down or stop as necessary,
with the distance walked recorded at the end of the test.
However, at the end of the test patients should feel that
they could not have walked any further in the time allowed.
Measurements recorded include distance walked, pre- and
post-test SpO2 and heart rate. The Borg score was intro-
duced at the same time as the SWT at this centre and
therefore not available in patients performing the 6MWT.
Patients performing a 6MWT for the first time had two
practice walks at least 45 min apart.
Statistical analysis
In the analysis of the walk test data, survival was calculated
from the date of the walk test whereas in the analysis of
lung function, arterial blood gas measurement and BMI,
survival was calculated from the date on the transplant
assessment document as these were not necessarily per-
formed on the same day.
Cox proportional hazards modelling was used to assess the
effect of distance walked, pre-test heart rate, pre-test
oxygen saturation (SpO2) and pre-test Borg score (for SWT
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addition, regression analysis was used to see which markers
were likely to affect the distancewalked in the exercise tests.
Cox proportional hazards modelling was also used to
assess the effect of lung function (FEV1 and FVC), blood gas
analysis (PaO2, oxygen saturation and PaCO2) and BMI on
length of survival from the time of assessment.16,17 All
analysis was performed using Stata 9.2 (StataCorp, Texas).Results
A total of 407 patients were accepted onto the transplant
waiting list between 1988 and 2004, with 195 transplanted
during this period (82 between 1988e1993, i.e. 6MWT
cohort, and 113 between 1994e2004, i.e. SWT cohort). A
total of 212 died on the waiting list during this period. Of
the 212 patients, 146 patients had a documented walk test,
of which 121 were performed without oxygen supplemen-
tation. Survival post-walk test, distance walked and pre-
and post-test SpO2 were available on all 121 patients.
Of these, 77patients (35male, 42 female,meanage 25 yrs)
had a shuttle walk test and 44 patients (20 male, 24 female,
mean age 23 yrs) had a six-minute walk test (Table 1).
Pre-test (resting) and post-test heart rate (HR), Borg
scores, lung function data, arterial blood gas analysis and
BMI in patients performing either SWT or 6MWT are also
shown in Table 1. There was no significant difference in
microbiological status between cohorts with >90% isolating
Pseudomonas, 15% Burkholderia Cepacia Complex, 11%
MRSA and 11% MSSA in the study group as a whole. Many had
a mixed microbiological pattern.
Survival analysis
Post-shuttle walk test
Fig. 1 shows the KaplaneMeier survival estimate for time to
death of patients following the SWT. The median survival
time was 363 days, with an interquartile range (IQR)
between 226 and 566 days.Table 1 Characteristics of patients performing a shuttle walk o
Patient characteristics SWT
Patient No
Pre-test SpO2 (%) 77
Post-test SpO2 (%) 77
Walking distance (m) 77
Pre-test heart rate (bpm) 33
Post-test heart rate (bpm) 30
Pre-test Borg score 30
Post-test Borg score 30
FEV1 predicted (%) 76




Survival post-test (days) 77
naZ not applicable.Cox proportional hazard modelling was performed on
30 patients for whom data on distance walked, pre-test HR,
pre-test Borg score and pre-test SpO2 were available. These
four variables were included in the model. Analysis of the
model residuals showed that the proportional hazards’
assumptions were not violated.
Survival after the SWT was significantly associated with
a patient’s pre-test (resting) HR (Hazard ratioZ 1.04,
95%CI: 1.01e1.07, pZ 0.02). Distance walked and pre-test
SpO2 were not statistically significant when adjusted for
pre-test HR. The median (IQR) pre-test HR was 109 (95, 122)
bpm. Fig. 2 shows estimates of the survival function for
arbitrary resting HR values of 72, 109 and 120 bpm. The
effect of a resting tachycardia can clearly be seen. The Cox
model predicts that almost 85% of patients with a resting
HR of 120 bpm would have died by 500 days post-test. For
patients with a resting HR similar to the median for this
group i.e. 109 bpm, the model predicts that 70% would die
before 500 days, but for patients with a relatively healthy
resting HR of 72 bpm, only 25% would have died by this time
point.
Post-six-minute walk test
Fig. 3 shows the KaplaneMeier survival estimate for time
to death of patients following the 6MWT. The shape of the
curve is broadly similar to the shuttle walk test estimate,
but the length of survival was longer in this group. Median
survival time was 433 days with an interquartile range (IQR)
between 232 and 844 days.
Pre-test HR data was only available for 8 patients in the
6MWT group. Therefore pre-test HR was not used in
conjunction with any other model terms.18 Two models
were produced, one using only pre-test HR and another
looking at distance walked and pre-test SpO2. Neither
model violated the proportional hazards’ assumptions.
Survival after the 6MWT was also significantly associated
with pre-test HR (Hazard ratioZ 1.12; 95%CI: 1.01e1.24,
pZ 0.028). A separate model with distance walked and
pre-test SpO2 as the explanatory variables showed neither
measurement had a significant effect on survival time. Ther six-minute walk test.
6MWT
Median (IQR) Patient No Median (IQR)
92 (89, 94) 44 89 (83, 92)
81 (76, 86) 44 79 (73, 85)
300 (210, 385) 44 394 (240, 465)
109 (95, 122) 8 120 (105, 136)
141 (132, 150) 8 146 (130, 155)
1 (0.5, 3.0) na na
6 (4.5, 7.0) na na
22 (19, 26) 44 18 (16, 23)
40 (32, 48) 44 33 (25, 41)
7.7 (6.9, 8.8) 41 7.3 (6.4, 8.3)
5.8 (5.4, 6.5) 42 5.9 (5.3, 7.2)
17.2 (16.3, 18.8) 42 16.5 (15.5, 18.0)
363 (226, 566) 44 433 (232, 844)
Figure 3 KaplaneMeier survival estimate (- - - 95%CI) for
time to death of patients following the six-minute walk test.
Median survival 433 days (IQR 232, 844).
Figure 1 KaplaneMeier survival estimate (- - - 95%CI) for
time to death of patients following the shuttle walk test.
Median survival 363 days (IQR 226, 566).
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136). Fig. 4 shows KaplaneMeier survival estimate post-six-
minute walk test after splitting real observed data into two
groups above and below the median (due to limited data).
Even with the small amount of data available when
assessing the effect of HR on survival, there is a clear
difference in the predicted survival time of the two groups,
and this helps to corroborate the findings of the SWT data
above.
Regression analysis for shuttle walk test
Distance walked in the SWTwas significantly related to pre-
test (resting) HR (bZ4.73; 95%CI: 7.5 to 1.95,
p< 0.01) when linear regression was performed. Pre-test
SpO2 (bZ 15.04; 95%CI: 7.69e22.34, p< 0.01) and pre-test
Borg score (bZ59.12; 95%CI: 106.11 to 12.13,
pZ 0.016) were also significantly related to a patient’s
ability to walk further distances when performing linear
regression. On performing multiple regression pre-test HRFigure 2 Estimates of the survival function post-shuttle walk
test based on arbitary resting heart rate (HR) values of 72, 109
(cohort median) and 120 bpm. The cox model predicts that 85%
of patients with a resting HR of 120 bpm, 70% with a HR of
109 bpm but only 25% with a HR of 72 bpm would have died by
500 days.remained statistically significant (bZ3.92; 95%CI: 7.09
to 0.75, p< 0.02), whilst pre-test SpO2 (pZ 0.06) and
pre-test Borg score (pZ 0.53) were no longer significant at
the 5% level. Fig. 5 shows the linear regression relationships
between pre-test HR and SpO2 with distance walked. Shown
on the graph are the regression line and the 95% prediction
interval.
Effect of lung function, blood gas analysis and BMI on
length of survival from the time of transplant assessment
A significant association was observed between survival
post-assessment and PaO2 (Hazard ratioZ 0.59; 95%CI:
0.35e0.98, pZ 0.041) and arterial saturation (Hazard
ratioZ 1.19; 95%CI: 1.05e1.36, pZ 0.006) on room air but
not between survival and lung function or BMI at the time of
assessment in patients performing SWT. There was a signif-
icant association between survival and FVC (Hazard
ratioZ 1.08; 95%CI: 1.01 to 1.15, pZ 0.027), but not FEV1
(Hazard ratioZ 0.93; 95%CI: 0.85e1.01, pZ 0.08) or any
other parameter in patients performing 6MWT.Figure 4 KaplaneMeier survival estimate post-six-minute
walk test after splitting real observed data into two groups
above and below the median HR of 120 bpm. Despite small
numbers a clear difference in survival is shown.
Figure 5 Linear regression relationship (- - - 95%CI) between
pre-test heart rate (HR) and distance walked and pre-test
oxygen saturation by pulse oximetry and distance walked on
the shuttle walk test.
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In this study resting heart rate was the only consistent
characteristic in predicting survival in end-stage cystic
fibrosis (CF). An association between arterial oxygenation
and survival was observed in the cohort performing SWT but
not those performing 6MWT; and an association between
FVC and survival in the cohort performing 6MWT but not
those performing SWT. There was no association between
distance walked and survival when adjusted for resting
heart rate and no significant association between FEV1 or
BMI and survival in either cohort. Distance walked on SWT
was associated with resting heart rate, oxygen saturation
(as measured by pulse oximetry) and perceived level of
breathlessness (Borg score) but only the association
between heart rate and distance walked remained signifi-
cant when performing multiple regression.
As a measure of functional capacity in cardiorespiratory
disease an inverse relationship between resting sinus
tachycardia and survival and between SWT distance and
resting sinus tachycardia, hypoxia and Borg score is perhaps
not surprising but provides support for the use of these
parameters in the assessment of functional capacity in
patients with CF. There was no additional prognostic value
of utilising distance walked in walk tests in predicting
survival as part of transplant assessment.
As the SWT is perhaps less dependent on patient moti-
vation than the 6MWT it has been the preferred standard at
the Royal Brompton Hospital since its introduction in 1993.It has been validated in patients with chronic obstructive
airways disease (COPD), idiopathic pulmonary fibrosis and
CF.7,8,19,20 A significant correlation has been reported
between resting PaO2 and SWT performance in patients
with idiopathic pulmonary fibrosis.20 Peak oxygen
consumption as measured by full cardiopulmonary exercise
testing correlates with SWT distance in COPD and chronic
heart failure, and is often considered a more optimal field
exercise test than the 6MWT in predicting morbidity and
mortality from cardiorespiratory disease.11,21e23 Two
previous SWT studies in patients with heart failure report
a statistically significant cut off distance of 450 m, failure
to achieve this identified cardiac patients with a high short
term mortality.11,24 A strong correlation between walking
distance and survival has been reported by Ru¨ter et al. in
patients with end-stage CF performing a 12-min walk test.10
Initial analysis of our SWT data in the same manner as Ru¨ter
et al. using Spearman’s non-parametric correlation would
also provide a significant, but in our study, weak correlation
between walking distance and survival (rZ 0.24,
pZ 0.034). However, no significant correlation could be
demonstrated in patients performing a 6MWT and we were
unable to confirm any association after adjusting for pre-
test (resting) heart rate using the more robust statistical
analysis of Cox proportional hazards modelling. As in our
study, Ru¨ter et al. also observed an association between
resting oxygen saturation and distance walked but no
association between FEV1, PaCO2 or BMI and survival, they
also report a significant survival disadvantage of
walking< 700 m.10 Similarly, Kadikar et al. report that
a walking distance of <400 m during a 6MWT identifies CF
patients at increased risk of dying whilst on a transplant
waiting list, but they included patients utilising supple-
mental oxygen during the walk test.25 Supplemental oxygen
may enable patients to walk further by alleviating symp-
toms of breathlessness and improving exercise capacity,
a confounding variable and therefore only patients per-
forming walk tests on room air were included in our study.
Patients undergoing assessment between 1988 and 1993
performed a 6MWT whilst those assessed thereafter per-
formed a SWT. Advances in CF treatment and predicted
survival during our observation period preclude any direct
comparisons between these two cohorts, although patients
in the earlier 6MWT cohort did in fact have a longer median
survival (433 days) despite having slightly worse clinical
characteristics than the later SWT cohort (363 days).
Clearly, overall survival in terms of age at death has
improved since 1988 but this is likely a result of new
treatments delaying the need for transplant referral rather
than having a significant impact on survival thereafter.
Despite this the SWT data was collected over an 11-year
period and the authors acknowledge that this long obser-
vation period is a major limitation to the study. Other
limitations as a result of the retrospective nature of this
study must also be taken into account including the limited
resting HR data in the 6MWT cohort and the imprecision in
defining the timing of the last dose of bronchodilator
especially in relation to long-acting bronchodilators which
may have had some carry over effect. All patients included
were taking bronchodilators in one form or another,
although they were all asked to refrain from using them
before the test.
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forming both a SWT and 6MWTwould be required to provide
both direct comparison between the two walk tests and
provide sufficient data for multivariate analysis over
a much shorter observation period.
International guidelines for the selection of lung trans-
plant candidates are intended as a general statement and
based on consensus rather than higher levels of evidence-
based medicine.3,4 They are disease specific and suggest
that CF patients should be considered for referral if they
have an FEV1 30% predicted, or FEV1 30% predicted if
associated with rapid progressive clinical deterioration
e.g., rapid fall in FEV1, increasing hospitalisations and
intravenous antibiotic requirement, major haemoptysis
and/or increasing cachexia despite optimal medical
management.3,4 Resting hypoxia, PaO2< 7.3 kPa
(55 mmHg) and hypercarpnia, PaCO2> 6.7 kPa (50 mmHg)
were also identified as useful criteria based on a similarly
predicted two-year mortality of >50%.26 Similar guidelines
were followed at the Royal Brompton Hospital throughout
the study period, with selection criteria for transplantation
after acceptance on the transplantation waiting list based
on blood group, height and calculated thoracic capacity,
then severity as well as organ availability rather than FEV1
or other specific clinical characteristics.
FEV1 alone remains a poor predictor of the need for
referral for lung transplantation, with an FEV1> 30%
a relatively sensitive predictor of two-year survival but an
FEV1< 30% is a poor positive predictor of death.
5 A retro-
spective study of lung transplantation outcome in CF found
no survival benefit of lung transplantation when selection
criteria was based on FEV1< 30% alone.
27 A substantial
number of patients survive for many years with an
FEV1< 30% and thus referral criteria based solely on this
criterion as reported by Doershuk et al. may adversely
affect overall survival.28 Although there was a possible
effect of lung function on survival in the cohort performing
6MWT this was not observed in the cohort performing SWT.
It has been suggested that the rate of decline in lung
function is probably a better predictor of need for
referral.29
An association between arterial oxygenation (PaO2) and
saturation at the time of assessment with survival was
demonstrated in those performing a SWT but not those
performing a 6MWT. In contrast, oxygenation as measured
by pulse oximetry (SpO2) on the day of the exercise test was
not associated with survival in either cohort. These
measurements are not directly comparable as the exercise
test may have preceded transplant assessment by a number
of months if performed as part of an annual review and not
repeated for the transplant assessment.
It is clear that no single variable is predictive of
mortality, although a recent validated predicted mortality
model in 14,572 CF patients based on lung function and
clinical characteristics including age, height, sputum micro-
biology, number of hospitalisations and home intravenous
antibiotic courses found no additional benefit of this model
over FEV1< 30% predicted alone.
5 In contrast, a model
including the outcome of a 12-min walk test, resting heart
rate, FEV1, age and sex has been shown to be of some value
in predicting the life expectancy of children with end-stage
disease.30The underlying cause of sinus tachycardia in end-stage
CF is likely to be multi-factorial including the effects
hypoxia, hypercarbia, systemic inflammation and pulmo-
nary hypertension. Although cor pulmonale is invariably
a pre-terminal finding there is evidence of subclinical RV
dysfunction in end-stage CF.31,32 Indeed, we have previ-
ously demonstrated a strong relationship between hypoxia
and hypercarbia and right ventricular systolic and diastolic
dysfunction in the setting of consistent tachycardia and
increased cardiac output in this patient population.31 Other
factors to be considered include the presence of anaemia,
chronic beta-agonist usage and the potential effects of
autonomic neuropathy especially in those with CF-related
diabetes.Conclusions
It remains difficult to know when to list and subsequently
transplant patients, as a result of the fine balance between
the risk of dying on a waiting list and the post-operative risk
of curtailing a patient’s life. It is however, reasonable to
consider patients for lung transplantation with an
FEV1< 30% or fulfilling other criteria laid down by inter-
national consensus including rate of deterioration, arterial
blood gas analysis, frequency of intravenous antibiotics,
sputum microbiology and not least of all, quality of life.
Acknowledging the limitations of this retrospective study
resting heart rate was the only consistent parameter in
predicting a high risk of dying while waiting for trans-
plantation. It is appropriate, therefore, that clinicians
should pay more attention to this parameter when assessing
their patients.Conflict of interest statement
The authors have no financial, personal, academic or
intellectual conflicts of interest.
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